Related Experiment Videos
Targets for sepsis therapies: tumor necrosis factor versus interleukin-1
1Synergen Inc, Boulder.
Abstract:
Clinical testing of therapies for sepsis that target tumor necrosis factor and interleukin-1 is currently in progress. It is now clear from early clinical results that patients display a heterogeneous response to anti-cytokine therapies that may be related to the stage or severity of disease. Experimental results show that either cytokine may contribute to the metabolic derangements that lead to organ dysfunction in severe sepsis. They also provide a physiological basis for understanding the benefits of anti-cytokine therapy in the most severely ill patients.
Insights
Clinical trials targeting tumor necrosis factor and interleukin-1 for sepsis show varied patient responses. These anti-cytokine therapies may benefit severely ill patients by addressing metabolic derangements causing organ dysfunction.
Area of Science:
- Immunology
- Critical Care Medicine
- Pharmacology
Background:
- Sepsis is a life-threatening condition characterized by a dysregulated host response to infection.
- Tumor necrosis factor (TNF) and interleukin-1 (IL-1) are key pro-inflammatory cytokines implicated in sepsis pathogenesis.
- Current clinical trials are evaluating anti-cytokine therapies targeting TNF and IL-1 for sepsis treatment.
Purpose of the Study:
- To investigate the clinical efficacy of anti-cytokine therapies in sepsis.
- To explore the relationship between patient response, disease stage, and severity.
- To elucidate the physiological role of TNF and IL-1 in sepsis-induced organ dysfunction.
Main Methods:
- Clinical evaluation of patients receiving anti-TNF and anti-IL-1 therapies.
- Analysis of patient response based on disease severity and stage.
- Experimental investigation of cytokine contribution to metabolic derangements in severe sepsis models.
Main Results:
- Early clinical results indicate heterogeneous patient responses to anti-cytokine therapies.
- Patient response appears correlated with the stage or severity of sepsis.
- Experimental data suggest both TNF and IL-1 contribute to metabolic derangements leading to organ dysfunction in severe sepsis.
Conclusions:
- Anti-cytokine therapies targeting TNF and IL-1 show potential in sepsis management.
- Therapeutic benefits may be most pronounced in severely ill patients.
- Understanding cytokine roles provides a physiological basis for targeted anti-cytokine interventions in critical sepsis.